First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar

Tyenne Version Is Approved In SC And IV Formulations; Rival Biogen Is Yet To Launch

 
• By Dave Wallace

Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

Sprinters running off from starting blocks
Fresenius Kabi has been first to launch a US tocilizumab biosimilar • Source: Shutterstock

More from Products

More from Generics Bulletin